

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



北京市春立正達醫療器械股份有限公司

Beijing Chunlizhengda Medical Instruments Co., Ltd.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1858)

2026 FIRST QUARTERLY REPORT

This announcement is made by Beijing Chunlizhengda Medical Instruments Co., Ltd.* (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rules 13.09(2) and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) to provide shareholders of the Company and the public with the updated financial information of the Company. This announcement is also published on the website of the Shanghai Stock Exchange simultaneously.

The unaudited results (the “**First Quarterly Report**”) of the Group for the three months ended 31 March 2026 are provided. The financial information contained in the First Quarterly Report was prepared in accordance with the Accounting Standards for Business Enterprises of the People's Republic of China, and consists accounting data which has not been audited. Potential investors and shareholders of the Company are advised to pay attention to the underlying investment risks.

The First Quarterly Report is written in both Chinese and English. In the case of any discrepancies, the Chinese version of the First Quarterly Report shall prevail.

By order of the Board

Beijing Chunlizhengda Medical Instruments Co., Ltd.*

Shi Wenling

Chairman

Beijing, the PRC, 29 April 2026

As at the date of this announcement, the executive directors of the Company are Ms. Shi Wenling, Mr. Shi Chunbao, Ms. Yue Shujun and Mr. Xie Feng Bao; the non-executive director of the Company is Mr. Wang Xin; and the independent non-executive directors of the Company are Ms. Xu Hong, Mr. Wong Tak Shing and Mr. Weng Jie.

* *For identification purposes only*

Beijing Chunlizhengda Medical Instruments Co., Ltd.*

2026 First Quarterly Report

The Board of Directors of the Company and all Directors undertake that this announcement contains no false record, misleading statement or material omission, and assume legal responsibility for the truthfulness, accuracy and completeness of its contents in accordance with law.

IMPORTANT NOTICE

The Board of Directors of the Company, the Directors, senior management warrant that the content of this quarterly report is true, accurate and complete and contains no false record, misleading statement or material omission, and jointly and severally assume legal responsibility for the content of this report.

The person in charge of the Company, the person in charge of accounting affairs of the Company and the person in charge of the accounting department (financial controller) warrant the truthfulness, accuracy and completeness of the financial information contained in this quarterly report.

Whether the financial statements for the first quarter are audited

Yes No

1. KEY FINANCIAL DATA

(I) Key accounting data and financial indicators

Unit: Yuan Currency: RMB

| Item | Current Reporting Period | Corresponding period of last year | Percentage change of the Current Reporting Period as compared to the corresponding period of last year (%) |
|--|---|-----------------------------------|---|
| | | | |
| Revenue | 216,972,373.23 | 229,843,941.53 | -5.60 |
| Total profit | 68,014,570.80 | 64,486,939.64 | 5.47 |
| Net profit attributable to the shareholders of the listed company | 61,710,990.86 | 58,071,117.89 | 6.27 |
| Net profit attributable to the shareholders of the listed company after deducting non-recurring profit or loss | 58,869,012.49 | 52,698,123.38 | 11.71 |
| Net cash flows generated from operating activities | -10,928,054.43 | -75,343,585.60 | N/A |
| Basic earnings per share (RMB/share) | 0.16 | 0.15 | 6.67 |
| Diluted earnings per share (RMB/share) | 0.16 | 0.15 | 6.67 |
| Weighted average RONA (%) | 2.05 | 2.04 | Increase by 0.01 percentage point |
| Total investments in research and development | 26,538,690.18 | 26,897,460.32 | -1.33 |
| Percentage of research and development investment to revenue (%) | 12.23 | 11.70 | Increase by 0.53 percentage point |
| | At the end of the Current Reporting Period | At the end of last year | Percentage change at the end of the Current Reporting Period as compared to the end of last year (%) |
| Total assets | 3,631,768,019.93 | 3,661,134,861.13 | -0.80 |
| Owners' equity attributable to the shareholders of the listed company | 3,047,178,827.01 | 2,985,467,836.15 | 2.07 |

1. KEY FINANCIAL DATA (CONTINUED)

(II) Non-recurring profit or loss items and amounts

✓Applicable □Non applicable

Unit: Yuan Currency: RMB

| Non-recurring gain or loss item | Amount for the Reporting Period | Description |
|---|--|--------------------|
| Gain and loss from disposal of non-current assets, including write-off of provision for asset impairment | | |
| Government grants included in profit or loss for the current period, excluding government grants that are closely related to the normal operation of the Company, complying with the requirements of national policy, entitled as per the standard established, and those that have continuous effect to the profit and loss of the Company | 894,328.00 | |
| Except for effective hedging business conducted in the ordinary course of business of the Company, gain or loss arising from change in fair value of financial assets held by and financial liabilities arising from non-financial enterprises, and gain or loss arising from disposal of financial assets and financial liabilities | 2,337,534.25 | |
| Capital utilization fee received from nonfinancial enterprises included in current gain or loss | | |
| Gain or loss on entrusted investments or assets under management | | |
| Gain or loss on entrusted loans | | |
| Loss on assets due to force majeure events, such as natural disasters | | |
| Reversal of the impairment provision for receivables under independent impairment test | | |
| Investments of subsidiaries, associates and joint ventures in which the investment cost was less than the profit at fair value of identifiable net assets of the investees at the time of acquisition | | |
| Net gain or loss of subsidiaries for the current period from the beginning of the period to the date of consolidation arising from business consolidation under common control | | |

1. KEY FINANCIAL DATA (CONTINUED)

(II) Non-recurring profit or loss items and amounts (continued)

| Non-recurring gain or loss item | Amount for the Reporting Period | Description |
|--|---------------------------------------|-------------|
| Gain or loss on exchange of non-monetary assets | | |
| Gain or loss on debt restructuring | | |
| One-off expenses incurred by enterprises due to the discontinuity of relevant business activities, such as staff resettlement expenses | | |
| One-off effect on current profit or loss due to the adjustments to laws and regulations on tax and accounting | | |
| One-off share-based payment expenses recognised due to cancellation and modification of share incentive scheme | | |
| Gain or loss arising from changes in the fair value of employee benefits for cash-settled share-based payments, payable after the vesting date | | |
| Gain or loss arising from changes in fair value of investment properties under fair value method on subsequent measurement | | |
| Gain on transactions at unfair trading prices | | |
| Gain or loss from other contingencies which are not related to the Company's normal operations | | |
| Custody fee income from custody operations | | |
| Other non-operating income and expenses other than aforesaid items | | |
| Other gain or loss items within the definition of non-recurring profit or loss | 111,155.91 | |
| Less: Effect of income tax | 501,017.19 | |
| Impact of minority interests (after tax) | 22.60 | |
| | <hr/> | |
| Total | <u>2,841,978.37</u> | |

Reasons should be given for the Company defining the non-recurring gain or loss items with significant amount not set out in the Explanatory Announcement No. 1 on Information Disclosure by Companies Offering Securities to the Public - Non-recurring Gain or Loss along with non-recurring gain or loss items set out in the Explanatory Announcement No. 1 on Information Disclosure by Companies Offering Securities to the Public - Non-recurring Gain or Loss as recurring gain or loss items.

1. KEY FINANCIAL DATA (CONTINUED)

(II) Non-recurring profit or loss items and amounts (continued)

Applicable Not applicable

Unit: Yuan Currency: RMB

| Item | Amount | Reason(s) |
|---|---------------|---|
| Additional deduction of value-added tax for advanced manufacturing industry | 157,170.66 | Continuous impact on gains or losses of the Company |
| Government grants related to assets | 1,090,162.55 | Continuous impact on gains or losses of the Company |

(III) Description and reasons for the changes in key accounting data and financial indicators

Applicable Not applicable

| Item | Change percentage (%) | Main reason(s) |
|--|------------------------------|---|
| Net cash flows generated from operating activities | N/A | The net cash flows from operating activities of the Company have improved year-on-year, mainly due to the Company's reasonable control of operating expenses and refined optimisation of fund coordination and utilisation efficiency during the Reporting Period, resulting in a decrease in cash outflow from operating activities. |

2. INFORMATION OF SHAREHOLDERS

(A) Total number of ordinary shareholders, preferred shareholders with voting rights reinstated, and the shareholding of top ten shareholders

Unit: Share

| | | | |
|--|-------|--|-----|
| Total number of ordinary shareholders at the end of the Reporting Period | 7,673 | Total number of shareholders of preferred shares with voting rights reinstated (if any) at the end of the Reporting Period | Nil |
|--|-------|--|-----|

2. INFORMATION OF SHAREHOLDERS (CONTINUED)

(A) Total number of ordinary shareholders, preferred shareholders with voting rights reinstated, and the shareholding of top ten shareholders (continued)

| Shareholding of top ten shareholders (excluding lending shares through securities financing) | | | | | | | |
|---|---------------------------------------|-----------------------|-----------------------------|---|---|----------------------------------|--------|
| Name of shareholder | Nature of shareholder | Number of shares held | Shareholding percentage (%) | Number of shares held subject to trading restrictions | Number of Shares subject to trading restrictions that include lending shares through securities financing | Shares charged, tagged or frozen | |
| | | | | | | Status of shares | Number |
| Shi Chunbao | Domestic natural person | 120,209,043 | 31.34 | 0 | 0 | None | 0 |
| Yue Shujun | Domestic natural person | 95,447,900 | 24.88 | 0 | 0 | None | 0 |
| Beijing Panmao Investment Management Co., Ltd. - Panmao (Shanghai) Investment Center (LLP) (北京磐茂投資管理有限公司-磐茂(上海)投資中心(有限合夥)) | Domestic non-state-owned legal person | 17,250,000 | 4.50 | 0 | 0 | None | 0 |
| Huang Dong | Domestic natural person | 2,533,335 | 0.66 | 0 | 0 | None | 0 |
| Beijing Panmao Investment Management Co., Ltd. - Panxin (Shanghai) Investment Center (LLP) (北京磐茂投資管理有限公司-磐信(上海)投資中心(有限合夥)) | Domestic non-state-owned legal person | 2,500,000 | 0.65 | 0 | 0 | None | 0 |
| Bank of Communications Co., Ltd. (交通銀行股份有限公司)- ICBCCS Aged-care Industry Equity Securities Investment Fund (工銀瑞信養老產業股票型證券投資基金) | Domestic non-state-owned legal person | 1,760,788 | 0.46 | 0 | 0 | None | 0 |
| Huatai Securities (Shanghai) Asset Management Co., Ltd. (華泰證券資管) - Bank of China - Huatai Chunli Medical Family No. 1 the collective asset management plan for the shareholding of staff on Technology Innovation Board (中國銀行-華泰春立醫療家園1號科創板員工持股集合資產管理計劃) | Domestic non-state-owned legal person | 1,500,782 | 0.39 | 0 | 0 | None | 0 |

2. INFORMATION OF SHAREHOLDERS (CONTINUED)

(A) Total number of ordinary shareholders, preferred shareholders with voting rights reinstated, and the shareholding of top ten shareholders (continued)

| Shareholding of top ten shareholders (excluding lending shares through securities financing) | | | | | | | |
|--|---------------------------------------|-----------------------|-----------------------------|---|---|----------------------------------|--------|
| Name of shareholder | Nature of shareholder | Number of shares held | Shareholding percentage (%) | Number of shares held subject to trading restrictions | Number of Shares subject to trading restrictions that include lending shares through securities financing | Shares charged, tagged or frozen | |
| | | | | | | Status of shares | Number |
| Xie Huiming (謝慧明) | Domestic natural person | 1,308,955 | 0.34 | 0 | 0 | None | 0 |
| Hong Kong Securities Clearing Company Limited | Others | 1,171,420 | 0.31 | 0 | 0 | None | 0 |
| Bank of China Limited – ICBCCS Medical Healthcare Industry Stocks Securities Investment Fund (工銀瑞信醫療保健行業股票型證券投資基金) | Domestic non-state-owned legal person | 1,073,989 | 0.28 | 0 | 0 | None | 0 |

| Shareholding of top ten shareholders not subject to trading restrictions (excluding lending shares through securities financing) | | | |
|--|--|---------------------------------|-------------|
| Name of shareholder | Number of tradable shares held not subject to trading restrictions | Share class and number | |
| | | Share class | Number |
| Shi Chunbao | 120,209,043 | RMB-denominated ordinary shares | 120,209,043 |
| Yue Shujun | 95,447,900 | RMB-denominated ordinary shares | 95,447,900 |
| Beijing Panmao Investment Management Co., Ltd. - Panmao (Shanghai) Investment Center (LLP) (北京磐茂投資管理有限公司－磐茂(上海)投資中心(有限合夥)) | 17,250,000 | RMB-denominated ordinary shares | 17,250,000 |
| Huang Dong | 2,533,335 | RMB-denominated ordinary shares | 2,533,335 |
| Beijing Panmao Investment Management Co., Ltd. - Panxin (Shanghai) Investment Center (LLP) (北京磐茂投資管理有限公司－磐信(上海)投資中心(有限合夥)) | 2,500,000 | RMB-denominated ordinary shares | 2,500,000 |
| Bank of Communications Co., Ltd. (交通銀行股份有限公司) – ICBCCS Aged-care Industry Equity Securities Investment Fund (工銀瑞信養老產業股票型證券投資基金) | 1,760,788 | RMB-denominated ordinary shares | 1,760,788 |

2. INFORMATION OF SHAREHOLDERS (CONTINUED)

(A) Total number of ordinary shareholders, preferred shareholders with voting rights reinstated, and the shareholding of top ten shareholders (continued)

| Shareholding of top ten shareholders not subject to trading restrictions (excluding lending shares through securities financing) | | | |
|---|---|-----------------------------------|-----------|
| Name of shareholder | Number of tradable shares held not subject to trading restrictions | Share class and number | |
| | | Share class | Number |
| Huatai Securities (Shanghai) Asset Management Co., Ltd. - Huatai Chunli Medical Family No. 1 the collective asset management plan for the shareholding of staff on Technology Innovation Board (華泰春立醫療家園1號科創板員工持股集合資產管理計劃) | 1,500,782 | RMB-denominated ordinary shares | 1,500,782 |
| Xie Huiming (謝慧明) | 1,308,955 | RMB-denominated ordinary shares | 1,308,955 |
| Hong Kong Securities Clearing Company Limited | 1,171,420 | RMB-denominated ordinary shares | 1,171,420 |
| Bank of China Limited – ICBCCS Medical Healthcare Industry Stocks Securities Investment Fund (工銀瑞信醫療保健行業股票型證券投資基金) | 1,073,989 | RMB – denominated ordinary shares | 1,073,989 |
| Description of connected relationship or acting in concert of the above shareholders | <ol style="list-style-type: none"> As of the date of this announcement, Shi Chunbao and Yue Shujun are couple while Panmao and Panxin are the same controlling party. Apart from the above, the Company does not receive any statement from the top ten shareholders regarding the existence of connected relationship or agreement of acting-in concert; The Company is not aware of the existence of connected relationship among shareholders of tradable shares, or if they are the concerted parties under the stipulation of Measures for the Administration of Disclosure of Shareholder Equity Changes of Listed Companies. | | |
| Description on participation in margin financing and securities lending and lending shares for securities financing by top ten shareholders and top ten shareholders not subject to trading restrictions (if any) | None | | |

As of the end of the Reporting Period, the total number of ordinary shareholders of the Company amounted to 7,673, of which 7,658 holders of A Shares and 15 holders of H Shares;

The shares of the top 10 shareholders are held in Beijing Chunlizhengda Medical Instruments Co., Ltd.* Designated Security Account for Repurchase. As of 31 March 2026, the Designated Security Account for Repurchase held 1,376,851 shares, representing a shareholding percentage of 0.36%.

Lending of shares by shareholders involved in the securities financing business holding more than 5% of the shares, top 10 shareholders and top 10 shareholders of tradable shares not subject to trading restrictions

Applicable Not applicable

The changes of the top 10 shareholders and the top 10 shareholders of tradable shares not subject to trading restrictions resulted from lending/repayment for securities financing compared with the previous period

Applicable Not applicable

3. OTHER NOTICE

Other important information related to the operational conditions of the Company during the Reporting Period which requires the attention of the investors

Applicable Not applicable

4. QUARTERLY FINANCIAL STATEMENTS

(I) Type of auditor's opinion

Applicable Not applicable

(II) Financial statements

Consolidated balance sheet 31 March 2026

Prepared by: Beijing Chunlizhengda Medical Instruments Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

| Items | 31 March 2026 | 31 December 2025 |
|---|------------------|------------------|
| Current assets: | | |
| Monetary funds | 1,296,468,679.69 | 1,409,120,983.52 |
| Settlement reserve | | |
| Placements with banks and non-bank financial institutions | | |
| Held-for trading financial assets | 813,584,219.18 | 811,246,684.93 |
| Derivative financial assets | | |
| Notes receivable | 32,659,145.77 | 4,253,186.08 |
| Accounts receivable | 262,316,397.23 | 225,456,558.88 |
| Accounts receivable financing | | |
| Prepayment | 5,685,201.93 | 4,851,870.27 |
| Premium receivable | | |
| Reinsurance premium receivables | | |
| Reserves for reinsurance contract receivables | | |
| Other receivables | 692,414.55 | 222,608.48 |
| Including: Interests receivable | | |
| Dividends receivable | | |
| Financial assets purchased under agreements to resell | | |
| Inventories | 543,589,831.65 | 535,925,459.39 |
| Including: Data resources | | |

4. QUARTERLY FINANCIAL STATEMENTS (CONTINUED)

(II) Financial statements (continued)

Consolidated balance sheet (continued)

31 March 2026

Prepared by: Beijing Chunlizhengda Medical Instruments Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

| Items | 31 March 2026 | 31 December 2025 |
|---|-------------------------|-------------------------|
| Contract assets | | |
| Assets held for-sale | | |
| Non-current assets due within one year | | |
| Other current assets | 21,490,725.19 | 20,422,698.85 |
| Total current assets | 2,976,486,615.19 | 3,011,500,050.40 |
| Non-current assets: | | |
| Loans and advances | | |
| Debt investments | | |
| Other debt investments | | |
| Long-term receivables | | |
| Long-term equity investments | | |
| Other investments in equity instruments | | |
| Other non-current financial assets | | |
| Investment property | | |
| Fixed assets | 347,810,745.69 | 354,149,308.67 |
| Construction in progress | 133,966,658.46 | 129,329,592.01 |
| Productive biological assets | | |
| Oil & gas assets | | |
| Right-of-use assets | 3,090,957.67 | 3,840,500.22 |
| Intangible assets | 117,081,634.31 | 119,787,805.08 |
| Including: Data resources | | |
| Development expenditures | | |
| Including: Data resources | | |
| Goodwill | | |
| Long-term prepayments | | |
| Deferred income tax assets | 30,733,460.82 | 30,336,378.81 |
| Other non-current assets | 22,597,947.79 | 12,191,225.94 |

4. QUARTERLY FINANCIAL STATEMENTS (CONTINUED)

(II) Financial statements (continued)

Consolidated balance sheet (continued)

31 March 2026

Prepared by: Beijing Chunlizhengda Medical Instruments Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

| Items | 31 March 2026 | 31 December 2025 |
|---|-------------------------|-------------------------|
| Total non-current assets | <u>655,281,404.74</u> | <u>649,634,810.73</u> |
| Total assets | <u>3,631,768,019.93</u> | <u>3,661,134,861.13</u> |
| Current liabilities: | | |
| Short-term borrowings | | |
| Borrowings from central banks | | |
| Placements from banks and non-bank financial institutions | | |
| Held-for trading financial liabilities | | |
| Derivative financial liabilities | | |
| Notes payable | | |
| Accounts payable | 157,988,896.32 | 160,772,940.21 |
| Advances received | | |
| Contract liabilities | 68,782,882.15 | 82,166,218.34 |
| Financial assets sold under repurchase agreement | | |
| Deposits and placements from peers | | |
| Brokerage for trading securities | | |
| Brokerage for underwriting securities | | |
| Employee Remuneration payable | 68,574,900.14 | 68,607,725.23 |
| Taxes payable | 29,961,892.03 | 26,060,319.15 |
| Other payables | 105,266,250.52 | 181,961,490.77 |
| Including: Interests payable | | |
| Dividends payable | 10,254.55 | 80,260,246.29 |
| Handling fee and commission payables | | |
| Reinsurance premium payables | | |
| Liabilities held-for-sale | | |

4. QUARTERLY FINANCIAL STATEMENTS (CONTINUED)

(II) Financial statements (continued)

Consolidated balance sheet (continued)

31 March 2026

Prepared by: Beijing Chunlizhengda Medical Instruments Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

| Items | 31 March 2026 | 31 December 2025 |
|---|-----------------------|-----------------------|
| Non-current liabilities due within one year | 1,995,998.03 | 2,677,095.45 |
| Other current liabilities | 56,343,296.15 | 56,357,165.80 |
| Total current liabilities | 488,914,115.34 | 578,602,954.95 |
| Non-current liabilities: | | |
| Reserves for insurance contracts | | |
| Long-term borrowings | | |
| Bonds payable | | |
| Including: Preferred shares | | |
| Perpetual bonds | | |
| Lease liabilities | 245,211.06 | 598,047.04 |
| Long-term payables | | |
| Long-term employee remuneration payable | | |
| Estimated liabilities | | |
| Deferred gains | 81,404,775.63 | 82,494,938.18 |
| Deferred income tax liabilities | 12,530,372.68 | 12,446,459.51 |
| Other non-current liabilities | | |

4. QUARTERLY FINANCIAL STATEMENTS (CONTINUED)

(II) Financial statements (continued)

Consolidated balance sheet (continued)

31 March 2026

Prepared by: Beijing Chunlizhengda Medical Instruments Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

| Items | 31 March 2026 | 31 December 2025 |
|--|-------------------------|-------------------------|
| Total non-current liabilities | <u>94,180,359.37</u> | <u>95,539,444.73</u> |
| Total liabilities | <u>583,094,474.71</u> | <u>674,142,399.68</u> |
| Owners' equity (or shareholders' equity): | | |
| Paid-in capital (or share capital) | 383,568,500.00 | 383,568,500.00 |
| Other equity instruments | | |
| Including: Preferred shares | | |
| Perpetual bonds | | |
| Capital reserve | 1,044,799,419.83 | 1,044,799,419.83 |
| Less: Treasury shares | 20,008,021.82 | 20,008,021.82 |
| Other comprehensive income | | |
| Specific reserve | | |
| Surplus reserve | 225,066,727.32 | 225,066,727.32 |
| General reserve | | |
| Undistributed profits | <u>1,413,752,201.68</u> | <u>1,352,041,210.82</u> |
| Total equity attributable to owners (or equity attributable to shareholders) of the parent company | 3,047,178,827.01 | 2,985,467,836.15 |
| Minority interests | <u>1,494,718.21</u> | <u>1,524,625.30</u> |
| Total owners' equity (or shareholders' equity) | <u>3,048,673,545.22</u> | <u>2,986,992,461.45</u> |
| Total liabilities and owners' equity (or shareholders' equity) | 3,631,768,019.93 | 3,661,134,861.13 |

Items**31 March 2026 31 December 2025**

| | | |
|--|--|---|
| Person in charge of the Company: Shi Wenling | Person in charge for accounting affairs of the Company: Lu Hongyue (盧宏悦) | Person in charge of the accounting department: Lu Hongyue (盧宏悦) |
|--|--|---|

4. QUARTERLY FINANCIAL STATEMENTS (CONTINUED)**(II) Financial statements (continued)****Consolidated income statement***January to March 2026*

Prepared by: Beijing Chunlizhengda Medical Instruments Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

| Items | First quarter of 2026 | First quarter of 2025 |
|---|----------------------------------|----------------------------------|
| 1. Total operating revenue | 216,972,373.23 | 229,843,941.53 |
| Including: Operating revenue | 216,972,373.23 | 229,843,941.53 |
| Interest income | | |
| Premiums gained | | |
| Income from handling fee and commission | | |
| 2. Total operating cost | 152,107,504.30 | 163,972,970.30 |
| Including: Operating cost | 73,197,939.64 | 76,572,465.53 |
| Interest expense | | |
| Handling fee and commission expense | | |
| Surrender value | | |
| Net amount of compensation payout | | |
| Net amount of insurance contracts reserves withdrawn | | |
| Policy dividend payment | | |
| Reinsurance Expenses | | |

4. QUARTERLY FINANCIAL STATEMENTS (CONTINUED)

(II) Financial statements (continued)

Consolidated income statement (continued)

January to March 2026

Prepared by: Beijing Chunlizhengda Medical Instruments Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

| Items | First quarter of 2026 | First quarter of 2025 |
|--|--------------------------|--------------------------|
| Taxes and surcharge | 2,618,875.54 | 1,960,604.51 |
| Selling expenses | 39,159,180.28 | 46,121,370.37 |
| Administrative expenses | 11,140,244.15 | 16,587,602.35 |
| Research and development expenses | 26,538,690.18 | 26,897,460.32 |
| Financial expenses | -547,425.49 | -4,166,532.78 |
| Including: Interest expenses | | |
| Interest income | 3,599,755.52 | 4,176,613.37 |
| Add: Other gains | 2,286,983.35 | 2,183,975.41 |
| Investment income | | |
| (losses are presented as “-”) | | 3,217,026.86 |
| Including: Investment income from | | |
| associates and joint ventures | | |
| Gains from derecognition of | | |
| financial assets measured at | | |
| amortised cost | | |
| Foreign exchange gains | | |
| (losses are presented as “-”) | | |
| Net profit on hedging exposure | | |
| (losses are presented as “-”) | | |
| Gains on changes of fair value | | |
| (losses are presented as “-”) | 2,337,534.25 | 1,604,306.84 |
| Loss on credit impairment | | |
| (losses are presented as “-”) | -248,050.73 | -7,583,337.28 |
| Loss on asset impairment | | |
| (losses are presented as “-”) | -1,192,598.77 | -790,286.65 |
| Gains on disposal of assets | | |
| (losses are presented as “-”) | | -15,716.81 |
| 3. Operating profit (losses are presented as “-”) | 68,048,737.03 | 64,486,939.60 |
| Add: Non-operating income | 1,967.79 | 0.04 |
| Less: Non-operating expenses | 36,134.02 | |

4. QUARTERLY FINANCIAL STATEMENTS (CONTINUED)

(II) Financial statements (continued)

Consolidated income statement (continued)

January to March 2026

Prepared by: Beijing Chunlizhengda Medical Instruments Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

| Items | First quarter of 2026 | First quarter of 2025 |
|--|--------------------------|--------------------------|
| 4. Gross profit (total losses are presented as “-”) | 68,014,570.80 | 64,486,939.64 |
| Less: Income tax expenses | 6,333,487.03 | 6,456,361.94 |
| 5. Net profit (net losses are presented as “-”) | 61,681,083.77 | 58,030,577.70 |
| (I) Classified by continuity of operation | | |
| 1. Net profit for continuing operation (net losses are presented as “-”) | 61,681,083.77 | 58,030,577.70 |
| 2. Net profit for ceased operation (net losses are presented as “-”) | | |
| (II) Classified by ownership | | |
| 1. Net profit attributable to the shareholders of the parent company (net losses are presented as “-”) | 61,710,990.86 | 58,071,117.89 |
| 2. Non-controlling shareholders’ profit or loss (net losses are presented as “-”) | -29,907.09 | -40,540.19 |

6. Net other comprehensive income after tax

- (I) Net other comprehensive income after tax attributable to the owners of the parent company
1. Other comprehensive income that cannot be reclassified into profit or loss
 - (1) Changes in remeasurement on defined benefit plan
 - (2) Other comprehensive income that cannot be transferred to profit and loss under equity method
 - (3) Fair value change on other investments in equity instruments
 - (4) Fair value change on credit risk of the enterprise

4. QUARTERLY FINANCIAL STATEMENTS (CONTINUED)

(II) Financial statements (continued)

Consolidated income statement (continued)

January to March 2026

Prepared by: Beijing Chunlizhengda Medical Instruments Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

| Items | First quarter of 2026 | First quarter of 2025 |
|---|--------------------------|--------------------------|
| 2. Other comprehensive income that will be reclassified into profit or loss | | |
| (1) Other comprehensive income that can be transferred to profit and loss under equity method | | |
| (2) Fair value change on other debt investments | | |
| (3) Amounts of financial assets reclassified into other comprehensive income | | |
| (4) Provision on credit impairment on other debt investments | | |
| (5) Reserves of cash flow hedging | | |
| (6) Translation difference on financial statements denominated in foreign currencies | | |
| (7) Others | | |
| (II) Net other comprehensive income after tax attributable to non-controlling shareholders | | |
| 7. Total comprehensive income | 61,681,083.77 | 58,030,577.70 |
| (I) Total comprehensive income attributable to the owners of the parent company | 61,710,990.86 | 58,071,117.89 |
| (II) Total comprehensive income attributable to non-controlling shareholders | -29,907.09 | -40,540.19 |
| 8. Earnings per share: | | |
| (I) Basic earnings per share (RMB/share) | 0.16 | 0.15 |
| (II) Diluted earnings per share (RMB/share) | 0.16 | 0.15 |

For business combination under common control conducted during the current period, the acquiree achieved a net profit of RMB0.00 before the combination; the acquiree achieved a net profit of RMB0.00 during the previous period.

| | | |
|--|--|---|
| Person in charge of the Company: Shi Wenling | Person in charge for accounting affairs of the Company: Lu Hongyue (盧宏悦) | Person in charge of the accounting department: Lu Hongyue (盧宏悦) |
|--|--|---|

4. QUARTERLY FINANCIAL STATEMENTS (CONTINUED)

(II) Financial statements (continued)

Consolidated cash flow statement

January to March 2026

Prepared by: Beijing Chunlizhengda Medical Instruments Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

| Items | First quarter of 2026 | First quarter of 2025 |
|---|--------------------------|--------------------------|
| 1. Cash flows from operating activities: | | |
| Cash receipts from sale of goods and rendering of services | 141,900,211.93 | 154,928,044.70 |
| Net increase in the amounts of deposits from customers and placements from peers | | |
| Net increase in amounts due to central banks | | |
| Net increase in placements from other financial institutions | | |
| Cash received from the premium of original insurance contract | | |
| Net cash received from reinsurance business | | |
| Net increase in policyholder deposits and amount for investment | | |
| Cash received from interest, handling fee and commission | | |
| Net increase in placements from banks and non- bank financial institutions | | |
| Net increase in capital on business repurchased | | |

4. QUARTERLY FINANCIAL STATEMENTS (CONTINUED)

(II) Financial statements (continued)

Consolidated cash flow statement (continued)

January to March 2026

Prepared by: Beijing Chunlizhengda Medical Instruments Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

| Items | First quarter of 2026 | First quarter of 2025 |
|---|--------------------------|--------------------------|
| Net cash received on securities dealing agency services | | |
| Receipts of tax refund | | |
| Other cash receipts related to operating activities | 6,027,991.27 | 5,079,610.43 |
| Subtotal of cash inflow from operating activities | <u>147,928,203.20</u> | <u>160,007,655.13</u> |
| Cash payments for goods purchased and services received | 67,926,712.43 | 118,196,154.09 |
| Net increase in loans and advances from customers | | |
| Net increase in amounts deposited in central bank and peers | | |
| Cash payment on compensation payout in original insurance contract | | |
| Net increase in placements with banks and non- bank financial institutions | | |
| Cash payment on interest, handling fee and commission | | |
| Cash payment for policy dividend | | |
| Cash paid to and on behalf of employees | 45,064,602.87 | 56,582,807.71 |
| Taxes paid | 13,613,723.34 | 10,570,701.96 |
| Other cash payments related to operating activities | 32,251,218.99 | 50,001,576.97 |
| Subtotal cash outflow from operating activities | <u>158,856,257.63</u> | <u>235,351,240.73</u> |
| Net cash flows from operating activities | <u>-10,928,054.43</u> | <u>-75,343,585.60</u> |
| 2. Cash flows from investing activities: | | |
| Cash received from disinvestments | | 744,000,000.00 |
| Cash received from return on investments | | 6,619,109.04 |

4. QUARTERLY FINANCIAL STATEMENTS (CONTINUED)

(II) Financial statements (continued)

Consolidated cash flow statement (continued)

January to March 2026

Prepared by: Beijing Chunlizhengda Medical Instruments Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

| Items | First quarter of 2026 | First quarter of 2025 |
|---|--------------------------|--------------------------|
| Net cash received from the disposal of fixed assets, intangible assets and other long-term assets | | |
| Net cash received from the disposal of subsidiaries and other business units | | |
| Other cash receipts related to investing activities | | |
| Subtotal of cash inflow from investing activities | | 750,619,109.04 |
| Cash paid for acquiring fixed assets, intangible assets and other long-term assets | 19,994,053.20 | 18,309,973.69 |
| Cash payments for investments | | |
| Net increase in pledged loans | | |
| Net cash payments for acquisitions of subsidiaries and other business units | | |
| Other cash payments related to investing activities | | |
| Subtotal of cash outflow from investing activities | 19,994,053.20 | 18,309,973.69 |
| Net cash flows from investing activities | -19,994,053.20 | 732,309,135.35 |

3. Cash flows from financing activities:

Cash received from investments

4. QUARTERLY FINANCIAL STATEMENTS (CONTINUED)

(II) Financial statements (continued)

Consolidated cash flow statement (continued)

January to March 2026

Prepared by: Beijing Chunlizhengda Medical Instruments Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

| Items | First quarter of 2026 | First quarter of 2025 |
|---|--------------------------|--------------------------|
| Including: Cash received by subsidiaries from non-controlling shareholders' investments | | |
| Cash received from borrowings | | |
| Other cash receipts related to financing activities | | |
| Subtotal of cash inflow from financing activities | | |
| Cash repayment of debts | | |
| Cash paid for distribution of dividends, profits or for interest expenses | 80,249,991.74 | |
| Including: Dividends and profit paid by subsidiaries to non-controlling shareholders | | |
| Other cash payments related to financing activities | 1,159,250.21 | 35,877.14 |
| Subtotal of cash outflow from financing activities | 81,409,241.95 | 35,877.14 |
| Net cash flows from financing activities | -81,409,241.95 | -35,877.14 |
| 4. Effect of foreign exchange rate changes on cash and cash equivalents | -320,760.32 | 87,041.01 |
| 5. Net increase in cash and cash equivalents | -112,652,109.90 | 657,016,713.62 |

| Items | First quarter of 2026 | First quarter of 2025 |
|--|----------------------------------|----------------------------------|
| Add: Opening balance of cash and cash equivalents | 1,402,472,486.98 | 1,139,017,650.66 |
| 6. Closing balance of cash and cash equivalents | 1,289,820,377.08 | 1,796,034,364.28 |

Person in charge of the
Company:
Shi Wenling

Person in charge for accounting
affairs of the Company:
Lu Hongyue (盧宏悦)

Person in charge of the
accounting department:
Lu Hongyue (盧宏悦)

Adjustments to the financial statements at the beginning of the year of the first implementation due to the first implementation of the new accounting standards or interpretation of accounting standards since 2026

Applicable Non applicable

The Board of Directors of Beijing Chunlizhengda Medical Instruments Co., Ltd.*
29 April 2026

* For identification purposes only